相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
at-20℃
- 库存:
99
- 抗体英文名:
Anti-Phospho-Histone H3 (pT11) Monoclonal antibody (N123/19)
- 规格:
50-100ug
小鼠抗Phospho-Histone H3(克隆号pT11)单克隆抗体(克隆号N123/19)上海圻明生物优势供应欢迎咨询。配对抗体小课堂:
Paired antibodies are two antibodies that can bind to an antigenic molecule at the same time. Specifically:
Paired antibodies are commonly used in sandwich ELISA experiments
An antigenic molecule usually has multiple epitopes, and different antibodies can target different epitopes
When two antibodies are able to bind to different epitopes of the same antigenic molecule at the same time, the two antibodies are called paired antibodies
However, not all antibodies against different epitopes can be paired antibodies. Sometimes, when an antibody binds to an antigen, it may cause the configuration of other binding sites to change, making it impossible for other antibodies to bind properly
Steric hindrance effects may also result in two antibodies with close binding sites not being able to bind to the antigen at the same time
Therefore, the preparation of paired antibodies usually requires two steps: first the antibody is prepared, and then the paired antibody is screened
Screening of paired antibodies is typically performed using a sandwich ELISA method of bispecific antibodies, in which different combinations of antibodies are tested to determine which antibodies can be successfully paired
Paired antibodies have important applications in immunology research and diagnostics, especially in assays that require high specificity and sensitivity.

小鼠抗Phospho-Histone H3(克隆号pT11)单克隆抗体(克隆号N123/19)更多优势产品欢迎新老客户选购。
MAB1596 小鼠抗ASFV F317L单克隆抗体(克隆号1A012)
MAB1597 小鼠抗ASFV I177L单克隆抗体(克隆号1A013)
MAB1598 小鼠抗CSFV NS5B单克隆抗体(克隆号1A014)
MAB1599 小鼠抗CSFV NS5B单克隆抗体(克隆号1A015)
MAB1600 小鼠抗ASFV I10L单克隆抗体(克隆号1A016)
MAB1601 小鼠抗ASFV NS4A单克隆抗体(克隆号1A017)
MAB1602 小鼠抗ASFV NS4A单克隆抗体(克隆号1A018)
MAB1603 小鼠抗ASFV F778R单克隆抗体(克隆号1A019)
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验了 B7 家族的第三个成员 B7-H1(即日后的 PD-L1)[2]。2000 年,Tasuku Honjo 教授等人证明了 PD-L1 能与 PD-1 结合,进而抑制 T 细胞的增殖与细胞因子的分泌,负调控淋巴细胞的激活,从此,B7-H1 被正式命名为 PD-L1(陈列平教授则继续使用「B7-H1」命名)[3]。2003年,陈列平教授第一次成功地使用 PD-L1 封闭抗体联合 T 细胞回输技术治愈了约 60% 的头颈癌小鼠[4]。2014 年 12 月,首个应用于肿瘤治疗的抗 PD-1 抗体
50 与LFA-3(CD58)和CD59结合,T细胞活化 CD2R T11.3,9.1 Ta gp50 T细胞活化 CD3 T3,Leu4 T γ、δ、ε、ζ、η5种链分别为p26,20,19,16,21 T细胞活化 CD4 T4,Leu3a Tsub gp55 与MHCⅡ类分子结合,信号转导,HIV受体 CD5 T1,UCHT2,T101,Leu1 T,Bsub gp67(小鼠Lyt-1类同物) 与CD72结合,T细胞信号转导 CD6 T12,T411 Tsub,Bsub gp100 ? CD7 3A
50 与LFA-3(CD58)和CD59结合,T细胞活化 CD2R T11.3,9.1 Ta gp50 T细胞活化 CD3 T3,Leu4 T γ、δ、ε、ζ、η5种链分别为p26,20,19,16,21 T细胞活化 CD4 T4,Leu3a Tsub gp55 与MHCⅡ类分子结合,信号转导,HIV受体 CD5 T1,UCHT2,T101,Leu1 T,Bsub gp67(小鼠Lyt-1类同物) 与CD72结合,T细胞信号转导 CD6 T12,T411 Tsub,Bsub gp100 ? CD7 3A
技术资料暂无技术资料 索取技术资料








